Table 1.

All treatments install immunological memory

Treatment	Original tumor	Rechallenge	Rechallenge site	Number protected
IL-2	AE17	AE17	Tumor site	9/10
IL-2	AE17-sOVA	AE17	Tumor site	4/6
IL-2	AE17-sOVA	AE17-sOVA	Tumor site	3/4
IL-2	AE17	AE17	Contralateral	10/12
IL-2	AE17-sOVA	AE17	Contralateral	4/6
anti-CD40 Ab	AE17	AE17	Tumor site	4/4
anti-CD40 Ab	AE17	AE17	Contralateral	3/3
IL-2/anti-CD40 Ab	AE17	AE17	Tumor site	13/13
IL-2/anti-CD40 Ab	AE17-sOVA	AE17	Tumor site	6/6
IL-2/anti-CD40 Ab	AE17	AE17	Contralateral	9/9
IL-2/anti-CD40 Ab	AE17-sOVA	AE17	Contralateral	4/4

C57BL/6J mice inoculated with 5 × 10⁵ AE17 tumor cells s.c. on day 0 were left to develop tumors ranging from 16 to 40 mm² before therapy commenced. Treatment regimens consisted of three i.t. injections per week for 2 weeks with PBS (the diluent control), IL-2 (20 μg/dose into small tumors) or anti-CD40 Ab (40 μg/dose into small tumors) as monotherapies, as well the IL-2/anti-CD40 Ab combination (into large tumors). Mice with complete tumor regression after treatment were left for varying periods of time ranging from two to 12 months and then rechallenged with 5 × 10⁵ AE17 or AE17-sOVA cells at either the original tumor implantation site or at the contralateral site. Shown are the number of mice protected from the total that were rechallenged in each of the different treatment groups